Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with
All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median
All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median